WASHINGTON– As far as cellular processes go, mitosis seems like a natural target for cancer drugs. "Its major business is cell growth," Genentech Inc.'s Peter Jackson told the audience at the annual meeting of the American Association for Cancer Research (AACR). It's got kinases – lots of kinases. And there is a "vast array" of traditional chemotherapies that hits some aspect of the cell cycle. But to date, clinical results of inhibiting cell cycle progression have been less successful than the
By Anette Breindl | BioWorld Today | Wednesday, April 10, 2013
It's website, though, still prominently notes, "We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching $261 million...One involved a financial software company (Longtop Financial Technologies Ltd.) that was delisted by the New York Stock Exchange in August 2011
By Larry Schuster | BioWorld International | Wednesday, April 10, 2013
It's website, though, still prominently notes, "We are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching $261 million...One involved a financial software company (Longtop Financial Technologies Ltd.) that was delisted by the New York Stock Exchange in August 2011
By Larry Schuster | BioWorld Today | Tuesday, April 9, 2013
Stemline Therapeutics Inc., of New York, said an ongoing collaboration with the Dana-Farber Cancer Institute featuring SL-401, currently in late-stage testing for hematological malignancies such as blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia, has shown activity in an additional hematologic malignancy, multiple myeloma, in preclinical models
Stemline Therapeutics Inc., of New York, closed its IPO of 3.8 million shares, including the exercise in full of the overallotment option covering 497,647 shares, at a price of $10 per share
By Peter Winter | BioWorld Insight | Monday, April 8, 2013
Stemline Therapeutics Inc., of New York, closed its IPO of 3.8 million shares, including the exercise in full of the overallotment option covering 497,647 shares, at a price of $10 per share
By Peter Winter | BioWorld Today | Monday, April 8, 2013
Vertex Pharmaceuticals Inc., of Cambridge, Mass., agreed with Bristol-Myers Squibb Co., of New York, to carry out Phase II studies of hepatitis C virus treatment regimens that contain Vertex's nucleotide analogue polymerase inhibitor VX-135
CEO Thomas Okarma, who ran Geron for more than a decade, is shooting for the New York Stock Exchange, where the company's shares would be listed under the symbol "AST...Okarma is on the agenda at the Alliance for Regenerative Medicine's investor day in New York on April 17, where he pledged to provide more details
By Marie Powers | BioWorld Today | Friday, April 5, 2013
Proving Causation What helped Kaiser prevail where other payers asserting RICO claims have failed was its evidence of causation linking the New York company's off-label marketing to an increase in physician prescriptions
By Mari Serebrov | BioWorld Today | Friday, April 5, 2013
The Pfizer deal goes a step further than the Amgen agreement, which involved the development of a nanotechnology-based therapeutic for solid tumors, with up-front and development milestones totaling $46.5 million plus $134 million in potential regulatory and sales milestones for the first therapeutic indication. (See BioWorld Today, Jan. 9, 2013.) New York-based Pfizer took an exclusive option to develop and commercialize multiple Accurins following collaborative preclinical research between
By Marie Powers | BioWorld Today | Thursday, April 4, 2013
Anaeropharma Science Inc., of Tokyo, initiated a Phase I trial of APS001F in U.S. patients with advanced or metastatic solid tumors whose disease is no longer responsive to available treatments. The dose-escalation trial is designed to evaluate the safety, tolerability and efficacy of APS001F, a living recombinant bifidobacterium designed to express the cytosine deaminase gene in tumors. The therapy is expected to limit the systemic toxicity of the antitumor agent 5-FU. Convergence
about 21% of Actinium's shares were exchanged for about 4.3M shares Callisto Pharmaceuticals Inc. (New York) Synergy Pharmaceuticals Inc. (New York) 7/24/12 1/16/13 ND Synergy acquired Callisto with each outstanding share of Callisto being exchange for 0.1799 shares of Synergy, and the 22.3M Synergy shares held by Callisto being cancelled Cangenix Ltd. (Mechelen, Belgium) Galapagos NV (Mechelen, Belgium) 1/16/13 1/16/13 £1 ($1.6) Galapagos is paying $1.6M up front for Cangenix Cypress
Islet Sciences Inc., of New York, added Eitan Akirav to its scientific advisory board...Keryx Biopharmaceuticals Inc., of New York, appointed Amit Sharma vice president of medical affairs
NeoStem Inc., of New York, said it was awarded the second year of a two-year grant totaling $595,252 from the National Institute of Allergy and Infectious Diseases for the development of human, autologous, pluripotent very small embryonic-like (VSEL) stem cells as a countermeasure to radiation threats...The company also said it requested trading of its ADS on the New York Stock Exchange to be suspended, as of March 28
Pfizer Inc., of New York, said the European Commission granted conditional marketing authorization for Bosulif (bosutinib) for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors and for whom Gleevec (imatinib, Novartis AG), Tasigna (nilotinib, Novartis AG) and Sprycel (dasatinib, Bristol-Myers Squibb Co.) are not considered appropriate
KineMed Inc., of Emeryville, Calif., said it renewed a nonexclusive research collaboration with Pfizer Inc., of New York, to advance approaches for treating metabolic disease, in particular Type II diabetes
3SBio Inc., of Shenyang, China, called an extraordinary general meeting of shareholders for April 25 to vote on the merger plan with Decade Sunshine Ltd. and its wholly owned subsidiary Decade Sunshine Merger Sub. The merger would result in 3SBio becoming a privately held subsidiary of Decade Sunshine Ltd., with its American Depository Shares no longer listed on the Nasdaq Global Market. The company's board of directors approved the merger agreement and recommended that shareholders vote to
BioWorld International | Wednesday, March 27, 2013
Based on PFS, we know that there is no way this drug will get to approval in any country in the world," said Jonathan Lewis, CEO of New York-based Ziopharm in a conference call
By Randy Osborne | BioWorld Today | Wednesday, March 27, 2013
WASHINGTON– As far as cellular processes go, mitosis seems like a natural target for cancer drugs. "Its major business is cell growth," Genentech Inc.'s Peter Jackson told the audience at the annual meeting of the American Association for Cancer Research (AACR). It's got kinases – lots of kinases. And there is a "vast array" of traditional chemotherapies that hits some aspect of the cell cycle. But to date, clinical results of inhibiting cell cycle progression have been less successful than the